Simcyp Posters RSS Feed

Tucker GT, Jackson PR, Lennard MS & Woods HF

Wed, 1 Aug 1990 00:00:00 GMT

Pharmacokinetic-pharmacogenetic modeling – a basis for the display and detection of polymorphisms in drug metabolism. In: Proceedings of European Consensus Conference on Pharmacogenetics. (Eds. Alvan G et al.) ECSC-EC-EAE 59-67 Brussels, Luxembourg, 1990.

Jackson PR, Tucker GT, Lennard MS & Woods HF

Wed, 1 Aug 1990 00:00:00 GMT

Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism – statistical methods. In: Proceedings of European Consensus Conference on Pharmacogenetics. (Eds. Alvan G et al.) ECSC-EC-EAE 43-52, Brussels, Luxembourg, 1990.

Tucker GT, Rostami-Hodjegan A & Jackson PR

Tue, 1 Aug 1995 00:00:00 GMT

The determination of drug metabolising status in vivo: pharmacokinetic and statistical issues.
In: Advances in Drug Metabolism in Man.
(Eds. Pacifies GM & Fracchia GN)
ECSC-EC-EAE 37-55, Brussels, Luxembourg, 1995.

Tucker GT, Rostami-Hodjegan A, Nurminen S and Jackson PR

Tue, 1 Aug 1995 00:00:00 GMT

Phenotyping populations: pharmacokinetic and statistical issues. In: Variability and Specificity in Drug Metabolism.
(Eds. Alvan G, Balant LP, Bechtel PR et al.)
ECSC-EC-EAE 191-203, Brussels, Luxembourg, 1995.

Tucker GT & Rostami-Hodjegan A

Fri, 1 Aug 1997 00:00:00 GMT

Metabolic variability in populations.
In: The Population Approach: measuring and managing variability in response, concentration and dose.
ECSC-EC-EAE 9-13, Brussels, Luxembourg, 1997.

Rostami-Hodjegan A

Thu, 1 Jul 1999 00:00:00 GMT

Incorporating variability into prediction of drug-drug interactions: moving from deterministic to a stochastic approach.
Mathematics in Medicine Initiative (MiMI), Compartmental Modelling and Pharmacokinetic Analysis
July 20th-22nd 1999, University of Warwick, United Kingdom.

Rostami-Hodjegan A, Tooley A & Tucker GT

Wed, 1 Nov 2000 00:00:00 GMT

Incorporating interindividual variability into in vitro – in vivo extrapolation.
7th EUFEPS Conference
Optimising Drug Development: Strategies to Assess Drug Metabolism/Transport Interaction Potential – Towards a Consensus
November 13th-15th 2000, Basel, Switzerland.

Yang JS, Rostami-Hodjegan A & Tucker GT

Sun, 1 Jul 2001 00:00:00 GMT

Prediction of fluconazole interaction with midazolam and triazolam: Incorporating population variability. Proceedings of the British Pharmacological Society July 3rd-5th 2001, Clinical Pharmacology Section, University College, Dublin.
Abstract published in: British Journal of Clinical Pharmacology A26, 52(4), 484, 2001.

Boyle J, Rostami-Hodjegan A, Ellis SW & Tucker GT

Sun, 1 Jul 2001 00:00:00 GMT

Reference values for human microsomal protein per gram of liver. Proceedings of the British Pharmacological Society July 3rd-5th 2001, Clinical Pharmacology Section, University College, Dublin.
Abstract published in: British Journal of Clinical Pharmacology A10, 52(4), 471, 2001.

Howgate EM, Proctor NJ, Rostami-Hodjegan A & Tucker GT

Sun, 1 Jun 2003 00:00:00 GMT

Prediction drug clearance allowing for the influence of P-glycoprotein activity using SIMCYP™.
The Proceedings of the 6th Congress of European Association for Clinial Pharmacology and Therapeutics.
152, 24th-28th June 2003, Istanbul.

Moghadamnia AA, Rostami-Hodjegan A, Abdul-Manap R, Wright CE, Morice AH & Tucker GT

Tue, 1 Jul 2003 00:00:00 GMT

Physiologically based modelling of inhibition of metabolism to assess the relative potency of drug and metabolite: dextromethorphan vs dextrorphan using quinidine Inhibition. British Journal of Clinical Pharmacology 56, 57-67, 2003.

Wilson ZE, Rostami-Hodjegan A, Burn JL, Tooley A, Boyle J, Ellis SW & Tucker GT

Tue, 1 Jul 2003 00:00:00 GMT

Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. British Journal of Clinical Pharmacology 56, 433-440, 2003.

Yang JS, Kjellsson M, Rostami-Hodjegan A & Tucker GT

Wed, 1 Oct 2003 00:00:00 GMT

Predicting metabolic drug-drug interactions for oral drugs: the impact of high transient concentrations of inhibitor and substrate during absorption. European Journal of Pharmaceutical Sciences 20, 223-232, 2003.

Proctor NJ, Smith CY, Rostami-Hodjegan A & Tucker GT

Mon, 1 Dec 2003 00:00:00 GMT

Population clearance prediction of 13 drugs using SIMCYP™.
Pharmacologist 44 (Supplement 1), LB87, 2002.

Yang J & Rostami-Hodjegan A

Sun, 1 Feb 2004 00:00:00 GMT

Accounting for first pass gut metabolism improves the relationship between lipophilicity and in vivo permeability.
LogP 2004: The 3rd Lipophilicity Symposium
February 29th-March 4th 2004, Zurich, Switzerland.

Jamei M, Yang J & Rostami-Hodjegan A

Sun, 29 Feb 2004 00:00:00 GMT

Inter and intra-individual variability in physiological parameters of gastro-intestinal tract has significant effects on the predicted fraction of dose absorbed.
LogP 2004: The 3rd Lipophilicity Symposium February 29th-March 4th 2004, Zurich, Switzerland.

Jamei M

Wed, 17 Nov 2004 00:00:00 GMT

Genetic algorithms and their applications in PK/PD data analysis.
Pharmacokinetics U.K. 2004 November 17th-18th 2004, Holiday Inn, Belfast, Northern Ireland.

Jamei M, Yang J, Rostami-Hodjegan A, & Tucker GT

Fri, 1 Apr 2005 00:00:00 GMT

Inter- and intra-individual variability in gastro-intestinal physiology has significant effects on the prediction of fraction of dose absorbed (fa).
3rd World Conference on Drug Absorption, Transport & Delivery
April 18th-20th 2005, Barcelona, Spain.

Dickinson GL, Lennard MS, Tucker GT & Rostami-Hodjegan A

Wed, 1 Jun 2005 00:00:00 GMT

The propagation of genetic polymorphism in CYP2C9 into warfarin pharmacokinetics: an integrated model.
Pharmaceutical Sciences Fair & Exhibition
June 12th-17th 2005, Nice, France.

Heydari A, Rowland-Yeo K, Lennard MS, Tucker GT & Rostami-Hodjegan A

Wed, 1 Jun 2005 00:00:00 GMT

The impact of study design on the estimation of parameters describing mechanism-based enzyme inhibition.
Pharmaceutical Sciences Fair & Exhibition
June 12th-17th 2005, Nice, France.

Jamei M, Yang J, Rostami-Hodjegan A & Tucker GT

Wed, 1 Jun 2005 00:00:00 GMT

Genetic algorithms and their applications in PK/PD data analysis. Pharmaceutical Sciences Fair & Exhibition
June 12th-17th 2005, Nice, France.

Howgate EM, Rowland-Yeo K, Proctor NJ, Rostami-Hodjegan A

Wed, 1 Jun 2005 00:00:00 GMT

Incorporation of inter-individual variability into the prediction of in vivo
drug clearance.
Pharmaceutical Sciences Fair & Exhibition
June 12th-17th 2005, Nice, France.

Wilson ZE, Ellis SW, Edwards RJ, Tucker GT & Rostami-Hodjegan A

Wed, 1 Jun 2005 00:00:00 GMT

Implications of the disparity in relative holo:apo-protein contents of different standards used for immuno-quantification of hepatic P450 3A4 (CYP3A4).
Pharmaceutical Sciences Fair & Exhibition
June 12th-17th 2005, Nice, France.

Ghanbari F, Rowland-Yeo K, Tucker GT & Rostami-Hodjegan A

Wed, 1 Jun 2005 00:00:00 GMT

A critical evaluation of the experimental design in reports of mechanism based inhibition (MBI) studies and the assessment of their implication for in vitro - in vivo extrapolation (IVIVE).
Pharmaceutical Sciences Fair & Exhibition
June 12th-17th 2005, Nice, France.

Lei Y, Wilson ZE, Crewe KH, Tucker GT & Rostami-Hodjegan A

Wed, 1 Jun 2005 00:00:00 GMT

Inter-individual variability in the catalytic activity of CYP3A4 per unit of
enzyme (kcat).
Pharmaceutical Sciences Fair & Exhibition
June 12th-17th 2005, Nice, France.

Shiran MR, Proctor NJ, Howgate EM, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A

Wed, 1 Jun 2005 00:00:00 GMT

Prediction of xenobiotic clearance in humans: in vitro - in vivo extrapolation (IVIVE) vs allometric scaling (AS).
Pharmaceutical Sciences Fair & Exhibition
June 12th-17th 2005, Nice, France.

Dickinson GL, Lennard MS, Tucker GT & Rostami-Hodjegan A

Tue, 1 Nov 2005 00:00:00 GMT

Simulations to assess the propagation of the impact of genetic polymorphism
in CYP enzymes into PK and PD outcomes: warfarin and dextromethorphan
as examples. AAPS Annual Meeting & Exposition
November 6th-10th 2005, Nashville, Tennessee, USA.

Barter ZE, Burns JL, Tucker GT & Rostami-Hodjegan A

Sun, 1 Jan 2006 00:00:00 GMT

Values of human hepatocellularity per gram of liver and associated variability for use in the prediction of human in vitro metabolic clearance.
Hepatocyte User Group (HUG) Meeting
January 26th-27th 2006, Copenhagen, Denmark.

Turner DB, Rostami-Hodjegan A, Tucker GT & Rowland-Yeo K

Thu, 1 Jun 2006 00:00:00 GMT

Prediction of non-specific hepatic microsomal binding from readily available physicochemical properties.
9th European ISSX Meeting
June 4th-7th 2006, Manchester, UK.

Dickinson GL, Lennard MS, Tucker GT & Rostami-Hodjegan A

Thu, 1 Jun 2006 00:00:00 GMT

The propagation of genetic polymorphism in CYP2C9 into tolbutamide pharmacokinetics: assessment using an intergrated model.
9th European ISSX Meeting
June 4th-7th 2006, Manchester, UK.

Ozdemir M, Crewe HK, Tucker GT & Rostami-Hodjegan A

Thu, 1 Jun 2006 00:00:00 GMT

The impact of dose-staggering on the inhibitory effect of ketoconazole on midazolam clearance, and its prediction using physiologically-based pharmacokinetic modelling.
9th European ISSX Meeting
June 4th-7th 2006, Manchester, UK.

Almond LM, Rowland-Yeo K, Howgate EM, Tucker GT & Rostami-Hodjegan A

Thu, 1 Jun 2006 00:00:00 GMT

Prediction of the oral clearance of S-warfarin in CYP2C9 genotypes from in vitro enzyme kinetic data.
9th European ISSX Meeting
June 4th-7th 2006, Manchester, UK.

Barter ZE, Crewe KH, Harlow JR, Lei Y, Tucker GT & Rostami-Hodjegan A

Thu, 1 Jun 2006 00:00:00 GMT

Differences in cytochrome P450 (CYP3A4) expression alone do not explain inter-individual variability in CYP3A mediated hepatic testosterone 6ß hydroxylase (TST6ßOH) activity.
9th European ISSX Meeting
June 4th-7th 2006, Manchester, UK.

Heydari A, Rowland-Yeo K, Lennard MS, Tucker GT & Rostami-Hodjegan A

Thu, 1 Jun 2006 00:00:00 GMT

Predicting drug interactions with selective serotonin reuptake Inhibitors (SSRIs): impact of non-specific binding and active uptake.
9th European ISSX Meeting
June 4th-7th 2006, Manchester, UK.

Van LM, Hammond C, Swales J, Wilson C, Rostami-Hodjegan A & Hargreaves JA

Thu, 1 Jun 2006 00:00:00 GMT

Estimation of the kinetic parameters of mechanism-based inhibition of CYP2D6 by methylenedioxymethamphetamine (MDMA) in cryopreserved human hepatocytes.
9th European ISSX Meeting
June 4th-7th 2006, Manchester, UK.

Yang J, Tucker GT, & Rostami-Hodjegan A

Thu, 1 Jun 2006 00:00:00 GMT

In-vitro stability of human recombinant cytochrome P450 enzymes.
9th European ISSX Meeting
June 4th-7th 2006, Manchester, UK.

Rowland-Yeo K, Jamei M, Yang J, Tucker GT & Rostami-Hodjegan A

Thu, 1 Jun 2006 00:00:00 GMT

Prediction of the inhibitory effects of ketaconazole and fluconazole on midazolam and zolpidem clearance from in vitro data using physiologically-based pharmacokinetic modelling.
In Vitro Stability of Human Recombinant Cytochrome P450 Enzymes
9th International Conference on Drug-Drug Interactions
June 20th-21st 2006, Seattle, WA, USA.

Van LM, Rowland-Yeo K, Lennard MS, Tucker GT & Rostami-Hodjegan A

Thu, 1 Jun 2006 00:00:00 GMT

Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine (MDMA): differences between expressed enzyme systems and human liver microsomes.
9th European ISSX Meeting
June 4th-7th 2006, Manchester, UK.

Jamei M, Rostami-Hodjegan A & Tucker GT

Thu, 1 Jun 2006 00:00:00 GMT

Co-operativity in the in vitro kinetics of cytochrome P450 (CYP) mediated drug metabolism will have minimal impact on in vivo metabolic clearance.
9th European ISSX Meeting
June 4th-7th 2006, Manchester, UK.

Johnson TN, Tucker GT & Rostami-Hodjegan A

Thu, 1 Jun 2006 00:00:00 GMT

Modelling of the age related changes of human CYP enzymes for predicting drug disposition in neonates, infants and children.
9th European ISSX Meeting
June 4th-7th 2006, Manchester, UK.

Perrett HF, Barter ZE, Edwards RJ, Lennard MS, Rostami-Hodjegan A & Tucker GT

Thu, 1 Jun 2006 00:00:00 GMT

The use of recombinantly expressed standards for immuno-quantification of hepatic CYP3A5 can result in an underprediction of CYP3A5 abundance.
9th European ISSX Meeting
June 4th-7th 2006, Manchester, UK.

Dickinson GL, Lennard MS, Tucker GT & Rostami-Hodjegan A

Fri, 1 Sep 2006 00:00:00 GMT

Assessing the propagation of CYP2C9 polymorphism into the PK/PD of warfarin using clinical trial simulations (CTS).
35th Annual Meeting of American College of Clinical Pharmacology September 17th-19th 2006, Cambridge, Massachusetts.
Abstract published in: Journal of Clinical Pharmacology A28, 46(9), 1067, 2006.

Almond LM, Rowland-Yeo K, Howgate EM, Tucker GT & Rostami-Hodjegan A

Fri, 1 Sep 2006 00:00:00 GMT

Utility of data from recombinant expressed genetic variants of CYPs in predicting the influence of genotype on in vivo drug kinetics - the case for S-Warfarin.
35th Annual Meeting of American College of Clinical Pharmacology September 17th-19th 2006, Cambridge, Massachusetts.
Abstract published in: Journal of Clinical Pharmacology A27, 46(9), 1067, 2006.

Johnson TN, Tucker GT & Rostami-Hodjegan A

Fri, 1 Sep 2006 00:00:00 GMT

Prediction of metabolic drug clearance in pediatric subjects and its sensitivity to different models for the development of CYP enzymes.
35th Annual Meeting of American College of Clinical Pharmacology September 17th-19th 2006, Cambridge, Massachusetts.
Abstract published in: Journal of Clinical Pharmacology A40, 46(9), 1070, 2006.

Ozdemir M, Crewe KH, Tucker GT & Rostami-Hodjegan A

Fri, 1 Sep 2006 00:00:00 GMT

The impact of dose-staggering on the inhibitory effect of ketoconazole on midazolam clearance, and its prediction using PBPK modelling.
35th Annual Meeting of American College of Clinical Pharmacology September 17th-19th 2006, Cambridge, Massachusetts.
Abstract published in: Journal of Clinical Pharmacology A18, 46(9), 1065, 2006.

Barter ZE, Rowland-Yeo K, Tucker GT & Rostami-Hodjegan A

Fri, 1 Sep 2006 00:00:00 GMT

A meta-analysis of CYP3A4 abundance in human liver: use of different standards contributes to apparent heterogeneity in reported values.
35th Annual Meeting of American College of Clinical Pharmacology September 17th-19th 2006, Cambridge, Massachusetts.
Abstract published in: Journal of Clinical Pharmacology A82, 46(9), 1080, 2006.

Barter ZE, Tucker GT, Rostami-Hodjegan A, Rowland-Yeo K & Howgate EM

Sun, 1 Oct 2006 00:00:00 GMT

Prediction of the oral clearance of midazolam using in vitro data from recombinantly expressed enzymes and inter system extrapolation factors.
Abstract published in: Drug Metabolism Reviews A71, 38(S2), 41, 2006.

Almond LM, Rowland-Yeo K, Dickinson GL, Howgate EM, Tucker GT & Rostami-Hodjegan A

Sun, 1 Oct 2006 00:00:00 GMT

Prediction of the oral clearance of tolbutamimde in individuals with different CYP2C9 genotypes using in vitro enzyme kinetic data.
14th North American ISSX Meeting
October 22nd-26th 2006, Rio Grande, Puerto Rico.

Jamei M, Finnoy AL, Tucker GT & Rostami-Hodjegan A

Wed, 2 May 2007 00:00:00 GMT

Bias in estimates of metabolic constants when applying the Michaelis-Menten equation to drugs exhibiting atypical enzyme kinetics.
Pharmaceutical Sciences World Congress (PSWC 2007)
Optimising Drug Therapy: An Imperative for World Health
22nd-25th April 2007, Amsterdam, Netherlands.

Yang J, Jamei M, Rowland Yeo K, Tucker GT & Rostami-Hodjegan A

Wed, 2 May 2007 00:00:00 GMT

Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time) -based enzyme inhibition.
Pharmaceutical Sciences World Congress (PSWC 2007)
Optimising Drug Therapy: An Imperative for World Health
22nd-25th April 2007, Amsterdam, Netherlands.

Lisa Almond, Karen Rowland Yeo, Eleanor Howgate, Geoffrey T Tuckerand Amin Rostami-Hodjegan

Wed, 2 May 2007 00:00:00 GMT

Mechanistic Prediction of HIV Drug-Drug Interactions in Virtual Populations from in vitro Enzyme Kinetic Data: Ritonavir and Saquinavir.

Rowland-Yeo K, Jamei M, Yang J, Tucker GT & Rostami-Hodjegan A

Thu, 24 May 2007 00:00:00 GMT

Prediction of in vivo drug interactions from in vitro enzyme kinetic data: time-based versus steady state simulations.
Pharmaceutical Sciences World Congress (PSWC 2007)
Optimising Drug Therapy: An Imperative for World Health
22nd-25th April 2007, Amsterdam, Netherlands.

Yang J, Jamei M, Rowland-Yeo K, Tucker GT & Rostami-Hodjegan A

Mon, 25 Jun 2007 00:00:00 GMT

Comparison of the “well-stirred” gut and the “QGut” models for predicting intestinal first-pass metabolism.
4th World Conference on Drug Absorption, Transport and Delivery
(4th WCDATD)
June 20th-22nd 2007, Kanazawa, Japan.

Jamei M, Yang J, Turner D, Rowland-Yeo K, Tucker GT & Rostami-Hodjegan A

Mon, 25 Jun 2007 00:00:00 GMT

A novel physiologically-based mechanistic model for predicting oral drug absorption: the advanced dissolution, absorption, and metabolism (ADAM) model.
4th World Conference on Drug Absorption, Transport and Delivery
(4th WCDATD)
June 20th-22nd 2007, Kanazawa, Japan.

Perrett HP, Barter ZE, Lennard MS, Tucker GT, Rostami-Hodjegan A

Mon, 25 Jun 2007 00:00:00 GMT

Assessing the relevance of genetic polymorphism in CYP3A5 in the kinetics of midazolam and tacrolimus: The importance of adequate study size.

Perrett HP, Barter ZE, Lennard MS, Tucker GT, Rostami-Hodjegan A

Mon, 25 Jun 2007 00:00:00 GMT

The impact of genetic polymorphism in CYP3A5 on the pharmacokinetics of the mixed CYP3A4/5 substrates midazolam and tacrolimus assessed by clinical trial simulation (CTS).

Barter ZE, Crewe KH, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A

Thu, 20 Sep 2007 00:00:00 GMT

Experimental considerations in determining Inter System Extrapolation Factors required for prediction of human drug clearance from recombinantly expressed enzymes. DMDG Open Meeting, Cambridge, UK

Polak S, Jamei M, Turner D, Tucker GT & Rostami-Hodjegan A

Thu, 4 Oct 2007 00:00:00 GMT

Impact of variability in estimates of drug diffusion coefficient on the prediction of fraction absorbed from the gut (fa) using the ADAM model (Simcyp v7.1).
EUFEPS & COST B25 Conference on Bioavailability and Bioequivalence:
Focus on Physiological Factors and Variability.
October 1st-2nd 2007, Athens, Greece.

Turner D, Jamei M, Tucker GT & Rostami-Hodjegan A

Thu, 11 Oct 2007 00:00:00 GMT

Supersaturation properties of poorly soluble weak bases are key factors in determining oral drug absorption: a simulation study of nifedipine using the ADAM model (Simcyp v7.1).
EUFEPS & COST B25 Conference on Bioavailability and Bioequivalence:
Focus on Physiological Factors and Variability.
October 1st-2nd 2007, Athens, Greece.

Johnson TN, Boussery K, Polak S, Tucker GT & Rostami-Hodjegan, A

Fri, 11 Apr 2008 00:00:00 GMT

Mechanistic models of human pharmacokinetics to predict the effects of liver cirrhosis on the clearance of nine drugs.
American Conference on Pharmacometrics.
March 9th-12th 2008, Tucson, Arizona, USA.

Neuhoff S, Yang J, Jamei M, Tucker GT & Rostami-Hodjegan A

Thu, 22 May 2008 00:00:00 GMT

Simulation of the effect of P-glycoprotein on drug absorption in the human gastrointestinal tract.
10th European ISSX Meeting. May 18th -21st 2008, Vienna, Austria.

Neuhoff S, Barter ZE, Rowland-Yeo K, Tucker GT & Rostami-Hodjegan A

Thu, 22 May 2008 00:00:00 GMT

In vitro-in vivo extrapolation of the clearance of drugs by glucuronidation: Scaling factors for recombinant UGT1A1 data.
10th European ISSX Meeting. May 18th -21st 2008, Vienna, Austria.

Yang J, Liao M, Shou M, Jamei M, Rowland-Yeo K, Tucker GT & Rostami-Hodjegan A

Thu, 22 May 2008 00:00:00 GMT

Cytochrome P450 turnover: methods for determining rates and implications for the prediction of drug interactions.
2nd Asian Pacific ISSX Meeting. May 11th-13th 2008, Shanghai, China.

Johnson TN, Boussery K, Tucker GT & Rostami-Hodjegan A

Fri, 23 May 2008 00:00:00 GMT

Prediction of the increased exposure to drugs in liver cirrhosis: a systems biology approach integrating prior information on disease with in vitro data on drug disposition. 10th European ISSX Meeting.
May 18th–21st 2008, Vienna, Austria.

Polak S, Jamei M, Turner DB, Yang J, Neuhoff S, Tucker GT & Rostami-Hodjegan A

Fri, 23 May 2008 00:00:00 GMT

Prediction of the in vivo behaviour of modified release formulations of metoprolol from in vitro dissolution profiles using the ADAM model (Simcyp®V8).
10th European ISSX Meeting. May 18th–21st 2008, Vienna, Austria.

Crewe HK, Barter ZE, Rowland-Yeo K, Tucker GT & Rostami-Hodjegan A

Fri, 20 Jun 2008 00:00:00 GMT

Comparison of the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9: determination of inter system extrapolation factors 10th European ISSX Meeting. May 18th–21st 2008, Vienna, Austria.

Perrett HF, Barter ZE, Lennard MS, Tucker GT & Rostami-Hodjegan A

Fri, 20 Jun 2008 00:00:00 GMT

What is the level of expression of CYP2D6 in human liver? Influence of different calibration standards of the estimation of CYP2D6 abundance. 10th European ISSX Meeting. May 18th–21st 2008, Vienna, Austria.